Polynovo Limited 

$1.6
34
+$0+0% Thursday 20:00

统计数据

当日最高
1.58
当日最低
1.58
52周最高
1.74
52周最低
0.51
成交量
6,000
平均成交量
1,612
市值
1.1B
市盈率
157.8
股息收益率
-
股息
-

即将到来

收益

23Aug预期
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q2 2024
-0.6
-0.4
-0.2
0
预期每股收益
0.00484271703596077
实际每股收益
0.00421316382128587

人们还关注

此列表基于关注CALZF的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

关于

Biotechnology
Health Technology
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Show more...
首席执行官
Paul Brennan
员工
254
国家
AU
ISIN
AU000000PNV0

上市公司